Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation.

Kuo JJ, da Silva AA, Tallam LS, Hall JE

Hypertension (Dallas, Tex. : 1979)5 Jan 2004Cited by 61 (Europe PMC)

PMID14707160DOI10.1161/01.hyp.0000111836.54204.93PepBankPUB-14707160

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, chronic intracerebroventricular MTII decreased food intake from 21 to 8 g/d by day 3.
In plain wordsIn rats, MTII infused into the brain cut daily food intake sharply by day 3.
Peptide
Melanotan II
Outcome
DecreaseFood intake
Study
ratn: not reported in source
Chronically instrumented rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 ng/h · intracerebroventricular · 11 daysAs given in this study (rat).
Measurements
Food intake
21 g/d
before MTII
Food intake
8 g/d
day 3 of MTII
Source sentences
Summary
MC3/4-R activation decreased food intake from 21+/-1 to 8+/-2 g/d by day 3 of MC3/4-R activation
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
Report a problemFND-1470716001
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, chronic intracerebroventricular MTII increased mean arterial pressure by an average of 8 mm Hg.
In plain wordsIn rats, MTII infused into the brain raised blood pressure by about 8 mm Hg on average.
Peptide
Melanotan II
Outcome
IncreaseMean arterial pressure
Study
ratn: not reported in source
Chronically instrumented rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 ng/h · intracerebroventricular · 11 daysAs given in this study (rat).
Measurements
Mean arterial pressure change
8 mm Hg
MTII
Source sentences
Summary
and increased MAP and HR by an average of 8+/-2 mm Hg and 9+/-5 bpm, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
Report a problemFND-1470716002
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, chronic intracerebroventricular MTII increased heart rate by an average of 9 bpm.
In plain wordsIn rats, MTII infused into the brain raised heart rate by about 9 beats per minute on average.
Peptide
Melanotan II
Outcome
IncreaseHeart rate
Study
ratn: not reported in source
Chronically instrumented rats
Outcome group
Heart function · Cardiovascular
Studied dose
10 ng/h · intracerebroventricular · 11 daysAs given in this study (rat).
Measurements
Heart rate change
9 bpm
MTII
Source sentences
Summary
and increased MAP and HR by an average of 8+/-2 mm Hg and 9+/-5 bpm, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
Report a problemFND-1470716003
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, glomerular filtration rate was unchanged during MTII infusion, both with vehicle and with adrenergic blockade.
In plain wordsIn rats, kidney filtration rate did not change during MTII infusion, with or without adrenergic blockers.
Peptide
Melanotan II
Outcome
No significant changeGlomerular filtration rate
Study
ratn: not reported in source
Chronically instrumented rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 ng/h · intracerebroventricular · 11 daysAs given in this study (rat).
Source sentences
Summary
Glomerular filtration rate was unchanged in both the vehicle-infused and adrenergic blocked rats during MC3/4-R activation.
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
Report a problemFND-1470716004

Studies that did not test the peptide alone3

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

05AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, adrenergic blockade did not alter the decrease in food intake caused by MTII.
In plain wordsIn rats, blocking adrenergic signals did not change the food intake drop caused by MTII.
Peptide
Melanotan II
Outcome
No significant changeMTII-induced decrease in food intake under adrenergic blockade
Study
ratn = 6
Chronically instrumented rats
Comparator
Vehicle (no blockade)
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Adrenergic blockade did not alter the MC3/4-R-mediated decrease in food intake but abolished the increases in MAP and HR (1+/-2 mm Hg and -12+/-5 bpm, respectively, compared with control).
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-1470716005
06AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, adrenergic blockade abolished the MTII-induced increase in mean arterial pressure.
In plain wordsIn rats, blocking adrenergic signals removed the blood pressure rise caused by MTII.
Peptide
Melanotan II
Outcome
DecreaseMTII-induced rise in mean arterial pressure under adrenergic blockade
Study
ratn = 6
Chronically instrumented rats
Comparator
Vehicle (no blockade)
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Adrenergic blockade did not alter the MC3/4-R-mediated decrease in food intake but abolished the increases in MAP and HR (1+/-2 mm Hg and -12+/-5 bpm, respectively, compared with control).
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-1470716006
07AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome
In rats, adrenergic blockade abolished the MTII-induced increase in heart rate.
In plain wordsIn rats, blocking adrenergic signals removed the heart rate rise caused by MTII.
Peptide
Melanotan II
Outcome
DecreaseMTII-induced rise in heart rate under adrenergic blockade
Study
ratn = 6
Chronically instrumented rats
Comparator
Vehicle (no blockade)
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Adrenergic blockade did not alter the MC3/4-R-mediated decrease in food intake but abolished the increases in MAP and HR (1+/-2 mm Hg and -12+/-5 bpm, respectively, compared with control).
1 context sentence(design, population, supporting numbers)
Summary · context
Five days after starting the vehicle or adrenergic blockade, the MC3/4-R agonist, MTII (10 ng/h), was infused ICV for 11 days followed by a 5-day recovery period.
In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.
Report a problemFND-1470716007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.